<DOC>
	<DOCNO>NCT02928393</DOCNO>
	<brief_summary>This Phase 2a , randomize , double-blind , placebo-controlled , parallel group study evaluate safety , efficacy pharmacodynamics basmisanil adult participant severe motor impairment follow ischemic stroke .</brief_summary>
	<brief_title>A Study Evaluate Safety Efficacy Basmisanil Adults With Severe Motor Impairment Following Ischemic Stroke</brief_title>
	<detailed_description />
	<mesh_term>Stroke</mesh_term>
	<criteria>Radiologic assessment confirm acute middle cerebral artery ischemic stroke Index stroke occur within past 34 day Inpatient male female Severe hemiparesis hemiplegia define FMMS score less equal ( &lt; /= ) 35 Sufficient speech , vision hearing participate study evaluations The presence reliable caregiver National Institute Health Stroke Scale ( NIHSS ) great ( &gt; ) 20 Severe aphasia prevents participant adequately complete study assessment Significant deficit prior stroke preexist motor deficit History epilepsy , neurosurgery , severe head trauma central nervous system ( CNS ) infection residual symptomatology require treatment last 12 month Known suspected clinical seizure postindex stroke History preexist dementia use medication dementia History clinically significant preexist psychiatric condition within 12 month prior stroke Due undergo carotid surgery within next 4 month Enrollment/participation interventional study ( clinical trial ) involve investigational drug ( unapproved ) nondrug treatment within prior 3 month 6 time halflife ( whichever longer ) Clinically relevant medical condition would likely interfere study conduct schedule assessment Contraindication Magnetic Resonance Imaging ( MRI ) condition render interpretation MRI difficult</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>